Туберкулез и ВИЧ: Двойное бремя для общественного здравоохранения
DOI:
https://doi.org/10.52692/1857-0011.2024.3-80.29Ключевые слова:
туберкулез, ВИЧ, коинфекция, диагностика, лечениеАннотация
Коинфекция туберкулезом (ТБ) и ВИЧ представляет собой серьезную глобальную проблему здравоохранения, с тяжелыми последствиями для заболеваемости и смертности. Сложное взаимодействие между этими двумя заболеваниями значительно увеличивает риск быстрого прогрессирования обеих болезней. Последние исследования подчеркивают необходимость ранней диагностики с использованием современных методов, таких как молекулярные экспресс-тесты, и своевременного начала антиретровирусной терапии для снижения заболеваемости и смертности. Интегрированные стратегии, включая профилактику и персонализированное лечение, являются ключевыми, особенно в контексте лекарственно-устойчивых форм. Несмотря на достигнутый прогресс, проблемы, связанные со стигматизацией, ограниченным доступом к лечению и лекарственными взаимодействиями, требуют постоянных усилий для улучшения клинических результатов.
Библиографические ссылки
Global tuberculosis report 2024. Geneva: World Health Organization; 2024.
Trăilescu A.M. Particularităţile clinico-radiologice ale tuberculozei la infectaţii hiv. Acta Medica Transilvanica. 2012; 2(2): 24-25
Афанасьев Е.И., Русских О.Е. Современные тенденции в эпидемиологии туберкулеза и ВИЧ- инфекции в мире и в Российской Федерации. РМЖ. 2021;3:24-26.
Lapshina I.S., Tsybikova E.B., Kulpesova M.A. epidemiology of tuberculosis combined with HIV infection, in the constituent entities of the Russian Federation with a low rate of tuberculosis prevalence. HIV Infection and Immunosuppressive Disorders.. 2022 Vol. 14, No. 2. P. 55–61,
Singh A, Prasad R, Balasubramanian V, Gupta N. Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives. HIV AIDS (Auckl). 2020 Jan 13;12:9-31.
Pokrovsky V. Tuberculosis and HIV/AIDS: the alien and the predator. Lancet 2017 Sep 30;390(10102):1618–9.
Sergevnin VI, Tukacheva OV, Mikova OE, et al. Long- Term Dynamics of HIV-Infected Mortality and Risk Factors of the Lethal Outcome in the Presence and Absence of Concomitant Tuberculosis. Epidemiology and Vaccinal Prevention.2022;21(6): 48–58.
Hamada Y, Getahun H, Tadesse BT, et. al. HIV- associated tuberculosis. Int J STD AIDS. 2021 Aug;32(9):780-790.
Чуйкова, М.М. Эпидемиологические аспекты ВИЧ-сочетанного туберкулеза. Вестник АГИУВ, № 1-2,2015, с. 61-65.
Duarte R, Lönnroth K, Carvalho C, et. al. Tuberculosis, social determinants and co-morbidities (including HIV). Pulmonology. 2018 Mar-Apr;24(2):115-119.
Matulyte E, Davidaviciene E, Kancauskiene Z, et al. The socio-demographic, clinical characteristics and outcomes of tuberculosis among HIV infected adults in Lithuania: A thirteen-year analysis. PLoS One. 2023 Mar 23;18(3):e0282046.
Zaidi I, Sarma P, Khayyam K. Sociodemographic factors affecting knowledge levels of tuberculosis patients in New Delhi. Journal of Family Medicine and Primary Care 13(11):p 5152-5158, November. 2024
TUBERCULOZA LA ADULT. Protocol clinic național (ediția VI) PCN- 123 Chișinău, 2024.
Manina V.V., Starshinova A.A., Panteleev A.M. Tuberculosis and hiv infection: epidemic situation in russia and in the world over the past ten years, features of detection and diagnosis. HIV Infection and Immunosuppressive Disorders. 2017;9(4):7-16.
Marius Zeeb, Burcu Tepekule, Katharina Kusejko, et al. The Swiss HIV Cohort Study , Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus in Switzerland, Clinical Infectious Diseases, Volume 77, Issue 9, 1 November 2023, p. 1303–1311.
Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long- term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health; 2017 ; 5:e1080–9.
World Health Organization; Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: W 2018.
World Health Organization. WHO Operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020. https://apps.who.int/iris/handle/10665/331525.
Zawedde-Muyanja S. Towards tuberculosis elimination: reaching the most at-risk populations with tuberculosis preventive therapy. Lancet Glob Health. 2023 Dec;11(12):e1834-e1835.
Sodeke, Olutomi and Shah, Sarita and Pals, et.al . Lower Tuberculosis Incidence Among People with HIV Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study. 2024.
Dlatu, N., Longo-Mbenza, B. & Apalata, T. Models of integration of TB and HIV services and factors associated with perceived quality of TB-HIV integrated service delivery in O. R Tambo District, South Africa. BMC Health Serv Res 2023 23, 804.
Global tuberculosis report 2022. Geneva: World Health organization; 2022.
Khan PY, Yates TA, Osman M, et al. Transmission of drug-resistant tuberculosis in HIV-endemic settings Lancet Infect Dis. 2019;19(3):e77-e88.
Martinez L, Woldu H, Chen C, et al. Transmission Dynamics in Tuberculosis Patients With Human Immunodeficiency Virus: A Systematic Review and Meta-analysis of 32 Observational Studies. Clin Infect Dis.;73(9):e3446-e3455.
WHO. The global plan to Stop TB 2006–2015. Geneva, Switzerland: WHO; 2006
Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: rapid communication. Policy update. Geneva: World Health Organization; 2020.
Gupta-Wright A, Fielding K, Wilson D, et al. Tuberculosis in hospitalized patients with human immunodefciency virus: clinical characteristics, mortality, and implications from the rapid urine-based screening for tuberculosis to reduce AIDS related mortality in hospitalized patients in Africa. In: Clin Infect Dis. 2020 Dec 17;71(10):2618-2626.
Geiger K., Patil A., Budhathoki C et. al. Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes. PLOS Glob Public Health. 2024 May 6;4(5):e0002714.
Pooranagangadevi N and Padmapriyadarsini C Treatment of Tuberculosis and the Drug Interactions Associated With HIV-TB Co-Infection Treatment. Front. Trop. Dis 2022. 3:834013.
Migliori GB Tiberi S. WHO drug-resistant TB guidelines 2022: what is new?. Int J Tuberc Lung Dis.; 2022 , 26: 590-591.
Walker NF, Stek C, Wasserman S, The tuberculosis- associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. Curr Opin HIV AIDS 2018.;13(6):512–21.
Efsen AMW, Schultze A, Miller RF, et.al TB: HIV study in EuroCoord. Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. J Infect. 2018 Jan;76(1):44-54.
Загрузки
Опубликован
Лицензия
Copyright (c) 2025 Вестник Академии Наук Молдовы. Медицина
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
